The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research. In ...

red blood cells The FDA has granted Priority Review for the Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease, a rare ...

CHRONIC lymphocytic leukemia and malignant lymphomas of the lymphocytic and follicular types may be relatively prolonged, benign diseases. They are inevitably fatal, however, and the final years are ...

Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...

"Our previous work showed that SARS-CoV-2 spike proteins lead to complement dysregulation by binding heparan sulfate and disrupting complement factor H…This doesn’t happen on red cells because red ...

Concerns of hemolysis continued to swirl around the Sapien 3 Ultra Resilia, with yet another report indicating such harm after transcatheter aortic valve replacement (TAVR). In a single-center ...

Is This Intravascular Immune Hemolysis? The term "immune" implies that the hemolysis is antibody-related. Because the type and antibody screen and the DAT were negative, the hemolysis was probably not ...

Hemolysis is the #1 source of preanalytical error and can impact potassium results—potentially leading to inappropriate or delayed patient treatment, unnecessary ...

The earliest description of an incompatible hemolytic transfusion reaction dates to the experimental start of transfusion therapy in the mid-17th century. While treating a nobleman who had episodes of ...